Overview

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.
Phase:
Phase 4
Details
Lead Sponsor:
United Therapeutics
Treatments:
Treprostinil